Thymectomy is the cornerstone in the treatment of thymic tumors and an accepted option for the management of myasthenia gravis. Different surgical approaches have been described, but the gold standard is represented by median sternotomy. In the last two decades, the development of minimally invasive surgery has led to an increased acceptance of thymectomy, especially for benign diseases. Robotic thymectomy seems a further step in the development and evolution of minimally invasive approaches. Since its introduction, different authors described their experience with robotic thymectomy, both for nonthymomatous myasthenia gravis and for thymic tumors. Available data show that robotic thymectomy may be considered a safe and feasible operation. In patients with nonthymomatous myasthenia, robotic thymectomy is effective and the long-term results are encouraging. The role of robotic thymectomy in patients affected by thymoma is still under evaluation, but the intermediate results seem promising both in terms of surgical and oncologic outcomes.
Keyphrases
- myasthenia gravis
- minimally invasive
- robot assisted
- end stage renal disease
- ejection fraction
- prostate cancer
- chronic kidney disease
- heart failure
- peritoneal dialysis
- adipose tissue
- metabolic syndrome
- patient reported outcomes
- combination therapy
- deep learning
- insulin resistance
- aortic valve
- silver nanoparticles
- glycemic control